Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 25 January 2018
Indication(s)
COMETRIQ is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Cushing's Syndrome
Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?
+ 2 more
Chronic Lymphocytic Leukaemia (CLL)
Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more
+ 1 more
Cardiovascular Metabolism Knowledge Centre
The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.
CDK 4/6 inhibitors in metastatic breast cancer
The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.
Chronic Obstructive Pulmonary Disease (COPD)
View highlights from recent congresses presented in new expert videos with leading physicians.
+ 7 more
Pain, Agitation and Delirium (PAD) Management
Discover the latest guidance on assessment and management of pain, agitation and delirium for patients requiring sedation.
+ 4 more
Migraine Knowledge Centre
The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.
Related Content
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
To assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
Added 3 years ago
Energy Balance in Craniopharyngioma-related Hypothalamic Obesity (ECHO)
The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on...
Added 3 years ago
MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
The purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat...
Added 5 years ago
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice (CaprelsaReg)
In this registry it is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or...
Added 5 years ago
DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer
The objectives of this project are to test whether alteration in DNA hypermethylation in plasma is: - a diagnostic marker...
Added 5 years ago
Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.
Until recently, there had not been an effective systemic chemotherapy for advanced differentiated thyroid carcinoma (DTC); lenvatinib, a multi-tyrosine kinase inhibitor, has been proven effective for DTC...
Added 1 year ago
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Introduction: Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poor effective. Several TKIs have been tested in clinical trials in pMTC patients.
Added 1 year ago
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA.
Background: The objective of the study was to reveal through pragmatic MCDA (EVIDEM) the contribution of a broad range of criteria to the value of the orphan drug lenvatinib for radioiodine refractory ...
Added 1 year ago
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.
Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular molecules involved in the modulation of angiogenesis and lymphangiogenesis: vascular endothelial growth factor receptor 1-3...
Added 1 year ago
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1...
Added 4 years ago
European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS
Thyroid ultrasound (US) is a key examination for the management of thyroid nodules. Thyroid US is easily accessible, noninvasive, and cost-effective, and is a mandatory step in the workup of thyroid nodules.
Added 7 months ago
Guidelines for the management of thyroid cancer
The intention is to provide guidance for all those involved in the management of patients with differentiated thyroid cancer (DTC) and some of the rarer thyroid cancers.
Added 4 years ago
2013 European Thyroid Association Guidelines for Cervical Ultrasound Scan and Ultrasound-Guided Techniques in the Postoperative Management of Patients with Thyroid Cancer
The main aim is to establish guidelines for both a cervical US scanning protocol and US-guided diagnostic and therapeutic procedures in patients with thyroid cancer.
Added 5 years ago
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
This guideline covers incidence and epidemiology, diagnosis, staging and management of differentiated thyroid cancer, medullary thyroid cancer, poorly differentiated thyroid carcinoma and anaplastic thyroid cancer.
Added 6 years ago
More information
Category | Value |
---|---|
Agency product number | EMEA/H/C/002640 |
Orphan designation | Yes |
Date First Approved | 21-03-2014 |
Type | Medicinal product subject to restricted medical prescription |
Marketing authorisation holder | Ipsen Pharma |
Warnings | This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reacti |